Dyslipidaemia and diabetes

Practical Diabetes International

Volumn 18, Issue 6, 2001, Pages 201-207

  Taylor, Roy ^a,b  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

HDL cholsterol; Macrovascular disease; Triglycerides; Type 2 diabetes

Indexed keywords

ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; ANTIOXIDANT; ASCORBIC ACID; ATORVASTATIN; BETA CAROTENE; BEZAFIBRATE; CERIVASTATIN; CHOLESTEROL; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PLACEBO; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFICACY; DYSLIPIDEMIA; FAMILY HISTORY; HEALTH SURVEY; HIGH RISK POPULATION; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFESTYLE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MEDICAL INFORMATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITION; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; SIDE EFFECT;

EID: 0034859567     PISSN: 13578170     EISSN: None     Source Type: Journal    
DOI: 10.1002/pdi.231     Document Type: Review

References (66)

1. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease
2. Assessing possible hazards of reducing cholesterol
3. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
4. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia
5. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
6. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPs/TexCAPs
7. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
8. AHA Scientific Statement. Diabetes and Cardiovascular Disease. A statement for healthcare professionals from the American Heart Association
9. Epidemiology of macrovascular disease in diabetes
10. Mechanisms determining course and outcome of diabetic patients who have had cute myocardial infarction
11. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: The GUSTO-1 experience
12. Mortality and morbidity during a five-year follow-up of diabetics with myocadial infarction
13. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease
14. Global burden of diabetes, 1995-2025. Prevalence, numerical estimates and projections
15. The changing face of macrovascular disease in non-insulin dependent diabetes mellitus: An epidemic in progress
16. Lipids and lipoproteins as coronary risk factors in non insulin dependent diabetes mellitus
17. Diabetes mellitus
18. Risk factors for arterial disease in diabetes: Dyslipidaemia
19. Insulin resistance and cardiovascular disease
20. American Diabetes Association technical review: Management of dyslipidaemia in adults with diabetes
21. The prospective cardiovascular Munster (PROCAM) study: Prevalence of hyperlipidaemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease
22. Lipid profile and outcome of diabetic patients with coronary artery disease in the BIP Study Registry
23. Diabetes, other risk factors and 12 year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial
24. Risk factors for coronary artery disease in non insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23)
25. LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL. The Strong Heart Study
26. Glycosylation of low density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism
27. Identification of multiple subclasses of plasma low density lipoproteins in normal humans
28. LDL heterogeneity: Implications for atherogenicity in insulin resistance and NIDDM
29. Low density lipoprotein subclass patterns and risk of myocardial infarction
30. Susceptibility of small dense low density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype
31. Oxidative modification of LL and atherogenesis
32. Epidemiology as a guide to clinical decisions: The association between triglyceride and coronary heart disease
33. Plasma triglyceride is a risk factor for cardiovascular disease independent of high density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies
34. Relation of high density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience)
35. Joint effects of triglycerides and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment
36. Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with type 2 diabetes
37. Type III hyperlipoproteinaemias (dysbetalipoprotein-aemia; remnant particle disease)
38. Postprandial lipaemia
39. Triglycerides and coronary heart disease - Has epidemiology given us the right answer?
40. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
41. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels. Subgroup Analysis in the Scandinavian Simvastatin Survival Study
42. The cost-effectiveness of lipid lowering in patients with diabetes: Results from the 4S trial
43. Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study
44. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analysis in the Cholesterol and Recurrent Events (CARE) Trial
45. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
46. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
47. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study
48. Coronary heart disease in NIDDM patients in the Helsinki Heart Study
49. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: The St Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study
50. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study
51. Status report of lipid-lowering trials in diabetes
52. Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials
53. Diabetes, lipids and coronary heart disease: What have we learnt from lipid lowering trials
54. Management of dyslipidaemia in adults with diabetes
55. Estimation of the concentration of low density lipoprotein in plasma without use of the preparative ultracentrifuge
56. Diabetic dyslipidaemia and its therapy
57. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
58. Prevention of coronary heart disease in clinical practice. Recommendations of the second joint task force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension
59. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from Euroaspire II Euro Heart Survey Programme
60. The treatment gap in coronary artery disease and heart failure: Community standards and the post discharge patient
61. Effects of an angiotensin converting enzyme inhibitor, ramipril on cardiovascular events in high risk patients
62. Pravastatin and the development of diabetes mellitus. Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study
63. Peroxisome proliferator-activity receptors: Nuclear control of metabolism